Drug Profile


Alternative Names: FV-100; Valnivudine

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cardiff University; FermaVir Pharmaceuticals; Rega Institute for Medical Research
  • Developer ContraVir Pharmaceuticals
  • Class Antivirals; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Herpes zoster; Postherpetic neuralgia

Most Recent Events

  • 03 Mar 2016 adverse events data from a phase III in Herpes zoster released by ContraVir Pharmaceuticals
  • 02 Nov 2015 ContraVir completes a phase I pharmacokinetics trial in Healthy volunteers in USA (NCT02322957)
  • 01 Jun 2015 Phase-III clinical trials in Herpes zoster in USA (PO) (NCT02412917)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top